Executive Chairman David Schlanger of Progyny Inc (PGNY, Financial) has sold 2,902 shares of the company on March 26, 2024, according to a recent SEC filing. The transaction was executed at an average price of $37.63 per share, resulting in a total value of $109,217.26.
Progyny Inc is a company that specializes in fertility and family building benefits solutions in the United States. It provides employers with benefits coverage for fertility treatments and family building services, including access to a network of fertility specialists.
Over the past year, David Schlanger has sold a total of 988,728 shares of Progyny Inc and has not made any purchases of the stock. This latest transaction continues a pattern of insider sales at the company, with a total of 40 insider sells and no insider buys occurring over the past year.
Shares of Progyny Inc were trading at $37.63 on the day of the insider's recent sale, giving the company a market capitalization of $3.668 billion. The price-earnings ratio of the stock stands at 61.27, which is above the industry median of 25.48 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is currently at 0.55, with a GF Value of $68.67. This indicates that Progyny Inc is significantly undervalued according to GuruFocus's intrinsic value estimate. The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
